Insight on AI – May 2026, Issue 11
Welcome to the May, Issue 11 edition of Artificial Vigilance, Essjay Solutions, Insight on AI, dedicated to helping pharmacovigilance professionals understand, engage with and adapt to the rapidly evolving world of artificial intelligence.
Tech News
The AI Model too Dangerous for the Public – Should we be Worried?
Anthropic’s latest AI system, Claude Mythos, has sparked concern across the technology and cybersecurity sectors after reports suggested it could outperform humans in identifying and exploiting software vulnerabilities. During testing, the model reportedly uncovered long-standing flaws and proposed potential attack strategies, raising questions about the risks posed by increasingly capable AI systems. While Anthropic restricted access to a small group of cybersecurity firms through Project Glasswing, concerns intensified after reports of unauthorised third-party access emerged. The case highlights both the promise and the risks of advanced AI in cybersecurity, reinforcing the importance of strong oversight, controlled deployment and continued investment in core security practices to protect critical infrastructure and patient data.
AI News
ChatGPT for Clinicians: A New Frontier for AI in Healthcare
OpenAI’s anticipated launch of ChatGPT for Clinicians signals a major step toward integrating generative AI into frontline healthcare workflows. Designed specifically for verified healthcare professionals, the platform focuses on clinical documentation, evidence synthesis and medical research support rather than general-purpose chatbot functions. As healthcare systems face growing administrative pressures and increasing volumes of medical data, AI tools like this may help clinicians reduce workload and access information more efficiently. However, the article also highlights ongoing concerns around hallucinations, explainability, bias and accountability, emphasising that AI should support rather than replace clinical judgement and must be integrated with strong governance and oversight.
Industry
AI and Digital Biomarkers Push Parkinson’s Trials into Real-World Monitoring
Clinical trials for Parkinson’s disease are evolving through the use of AI-powered monitoring, wearable technologies and biomarker testing. Annovis Bio and NeuroRPM have partnered to create a system capable of continuously tracking symptom fluctuations and medication adherence outside traditional clinic visits, generating detailed real-world insights into disease progression. The initiative also incorporates biomarker testing for phosphorylated alpha-synuclein, providing stronger pathological evidence of disease progression. These developments represent a broader shift toward patient-centric and data-driven clinical trials, while also highlighting how continuous monitoring and AI-generated data could eventually support pharmacovigilance teams in identifying emerging safety signals earlier and understanding patient experiences more comprehensively.
Regulation
AI Airlock is the Key to Building a Regulatory Pathway for AI in UK Healthcare
The UK MHRA’s AI Airlock programme is evolving into a central framework for evaluating and regulating AI medical devices. Designed as the UK’s first regulatory sandbox for healthcare AI, the initiative enables developers and regulators to collaboratively test emerging technologies and address regulatory challenges early in development. Backed by new multi-year government funding, the programme supports long-term testing of AI systems in real-world settings while exploring issues such as explainability, ongoing monitoring and change control plans for evolving AI systems. The initiative reflects a broader move toward adaptive, evidence-based regulation that balances innovation with patient safety and regulatory confidence.
